CV Sciences, Inc. Announces Brand New Distribution With Kroger and Expands Its Providing of Topical Items
PlusCBD™ Oil Roll-On establish at 945 Kroger shops in 17 U.S. States
VEGAS, June 12, 2019 (WORLD NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a supplier that is preeminent maker of hemp CBD items, is happy to announce further expansion of the industry-dominating PlusCBD™ Oil brand name utilizing the Kroger Co. (NYSE:KR).
The Company’s expanded distribution that is retail the launch of CV Sciences’ new PlusCBD Oil™ Roll-Ons in 945 Kroger shops across several of its retail banners, including Kroger, Dillons, Fry’s, Fred Meyer, King Sooper, Mariano’s, Pick ‘n Save, QFC and Smiths locations in 17 U.S. states. PlusCBD™ Oil Roll-On, for sale in 200mg CBD and further Strength 500mg formulations, is infused with concentrated CBD from agricultural hemp plant parts, warming camphor and menthol that is cooling. Made out of its Gold Formula focused complete spectrum hemp extract, the Roll-Ons offer high intensity help in an application that is easy-to-use. The Company’s best-selling PlusCBD™ Oil Extra Strength and Original Balms are also available at the participating Kroger places. To meet up with customer expectations of clean components, all PlusCBD™ Oil topical products have no phthalates, sulfates or parabens and are also made without artificial dyes or scents.
As discussed regarding the Company’s very first quarter 2019 profits turn to May 8, 2019, CV Sciences’ recent circulation gains consist of accessibility to PlusCBD™ Oil Extra Strength Balm in a short launch at CVS Pharmacy shops. By the addition of 945 Kroger places and distribution that is new other leading Food, Drug and Mass (FDM) retailers, at the time of June 12, 2019, PlusCBD™ Oil branded items are obtainable in 4,591 shops, up from 3,308 stores at the time of March 31, 2019, a rise of 38.7% within the prior 8 weeks.
“We are pleased to partner with Kroger and introduce our brand new Roll-On topical as we continue our quick expansion in to the FDM channel,” said Joseph Dowling, ceo. “Kroger, CVS Pharmacy, and other leading national retailers are keenly alert to the increased consumer need for hemp-based CBD items and they are partnering with CV Sciences due to our commitment that is unwavering to and quality. We’re at the start of what we believe may be acceptance that is broad of products across national FDM records therefore we look ahead to our continued growth even as we increase shop count and SKUs with your retail partners.”
PlusCBD™ Oil Extra Strength Balm ranks #1 in product sales both in the U.S. that is total Natural and complete U.S. MULO (Multi Outlet) during the last 52 months* among CBD services and products within Topical Analgesics, relating to SPINS and IRI data, correspondingly. Brightfield Group, a respected predictive analytics and researching the market company when it comes to CBD market, expects $1.3 billion in sales of CBD topicals in 2019, by having an ingredient growth that is annual of 169% from 2018 – 2022.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct company portions: a customer product unit centered on production, advertising and attempting to sell plant-based CBD products to a variety of market sectors; and a medication development division focused on developing and commercializing CBD-based novel therapeutics utilizing CBD. The Company’s PlusCBD™ Oil could be the top-selling model of hemp-derived CBD available on the market, relating to SPINS, the best provider of syndicated information and insights when it comes diamond cbd discount to natural, natural and specialty services and products industry. CV Sciences, Inc. has main workplaces and facilities in north park, California and Las vegas, nevada, Nevada. Extra information can be acquired from OTCMarkets.com or by visiting www.cvsciences.com.
This news release may include particular statements that are forward-looking information, as defined inside the concept of Section 27A of this Securities Act of 1933 and Section 21E of this Securities Exchange Act of 1934, and it is susceptible to the Safe Harbor developed by those parts. This product contains statements about anticipated future events and/or monetary outcomes which are forward-looking in general and at the mercy of dangers and uncertainties. Such statements that are forward-looking meaning involve dangers, uncertainties.